1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Next Generation Cancer Diagnostics Market, by Technology
6.1. Introduction
6.2. DNA Microarrays
6.3. Lab-on- a- chip & Reverse Transcriptase-PCR
6.4. Next Generation Sequencing
6.5. Protein Microarrays
6.6. qPCR & Multiplexing

7. Next Generation Cancer Diagnostics Market, by Cancer Type
7.1. Introduction
7.2. Breast Cancer
7.3. Cervical Cancer
7.4. Colorectal Cancer
7.5. Lung Cancer

8. Next Generation Cancer Diagnostics Market, by Function
8.1. Introduction
8.2. Cancer Screening
8.3. Companion Diagnostics
8.4. Prognostics
8.5. Risk Analysis
8.6. Therapeutic Monitoring

9. Next Generation Cancer Diagnostics Market, by Application
9.1. Introduction
9.2. Biomarker Development
9.3. CTC Analysis
9.4. Epigenetic Analysis
9.5. Genetic Analysis
9.6. Proteomic Analysis

10. California Next Generation Cancer Diagnostics Market
10.1. Introduction

11. Florida Next Generation Cancer Diagnostics Market
11.1. Introduction

12. Illinois Next Generation Cancer Diagnostics Market
12.1. Introduction

13. New York Next Generation Cancer Diagnostics Market
13.1. Introduction

14. Ohio Next Generation Cancer Diagnostics Market
14.1. Introduction

15. Pennsylvania Next Generation Cancer Diagnostics Market
15.1. Introduction

16. Texas Next Generation Cancer Diagnostics Market
16.1. Introduction

17. Competitive Landscape
17.1. FPNV Positioning Matrix
17.1.1. Quadrants
17.1.2. Business Strategy
17.1.3. Product Satisfaction
17.2. Market Ranking Analysis, By Key Player
17.3. Market Share Analysis, By Key Player
17.4. Competitive Scenario
17.4.1. Merger & Acquisition
17.4.2. Agreement, Collaboration, & Partnership
17.4.3. New Product Launch & Enhancement
17.4.4. Investment & Funding
17.4.5. Award, Recognition, & Expansion

18. Company Usability Profiles
18.1. Abbott Laboratories
18.1.1. Business Overview
18.1.2. Key Executives
18.1.3. Product & Services
18.2. Adaptive Biotechnologies Inc.
18.2.1. Business Overview
18.2.2. Key Executives
18.2.3. Product & Services
18.3. Agendia Nv
18.3.1. Business Overview
18.3.2. Key Executives
18.3.3. Product & Services
18.4. Agilent Technologies, Inc
18.4.1. Business Overview
18.4.2. Key Executives
18.4.3. Product & Services
18.5. Akadeum Life Sciences
18.5.1. Business Overview
18.5.2. Key Executives
18.5.3. Product & Services
18.6. Almac Group
18.6.1. Business Overview
18.6.2. Key Executives
18.6.3. Product & Services
18.7. Ambry Genetics
18.7.1. Business Overview
18.7.2. Key Executives
18.7.3. Product & Services
18.8. Becton, Dickinson And Co.
18.8.1. Business Overview
18.8.2. Key Executives
18.8.3. Product & Services
18.9. Biological Dynamics Inc.
18.9.1. Business Overview
18.9.2. Key Executives
18.9.3. Product & Services
18.10. Castle Biosciences Inc.
18.10.1. Business Overview
18.10.2. Key Executives
18.10.3. Product & Services
18.11. Danaher Corporation
18.11.1. Business Overview
18.11.2. Key Executives
18.11.3. Product & Services
18.12. Exosome Diagnostics, Inc.
18.12.1. Business Overview
18.12.2. Key Executives
18.12.3. Product & Services
18.13. F. Hoffmann-La Roche Ltd
18.13.1. Business Overview
18.13.2. Key Executives
18.13.3. Product & Services
18.14. GE Healthcare
18.14.1. Business Overview
18.14.2. Key Executives
18.14.3. Product & Services
18.15. Genomic Health, Inc.
18.15.1. Business Overview
18.15.2. Key Executives
18.15.3. Product & Services
18.16. Hologic, Inc
18.16.1. Business Overview
18.16.2. Key Executives
18.16.3. Product & Services
18.17. Illumina, Inc.
18.17.1. Business Overview
18.17.2. Key Executives
18.17.3. Product & Services
18.18. Janssen Global Services, LLC
18.18.1. Business Overview
18.18.2. Key Executives
18.18.3. Product & Services
18.19. Koninklijke Philips N.V.
18.19.1. Business Overview
18.19.2. Key Executives
18.19.3. Product & Services
18.20. Myriad Genetics, Inc.
18.20.1. Business Overview
18.20.2. Key Executives
18.20.3. Product & Services
18.21. Novartis AG
18.21.1. Business Overview
18.21.2. Key Executives
18.21.3. Product & Services
18.22. Opko Health, Inc.
18.22.1. Business Overview
18.22.2. Key Executives
18.22.3. Product & Services
18.23. Perkin Elmer, Inc.
18.23.1. Business Overview
18.23.2. Key Executives
18.23.3. Product & Services
18.24. Qiagen N.V.
18.24.1. Business Overview
18.24.2. Key Executives
18.24.3. Product & Services
18.25. Sysmex Corporation
18.25.1. Business Overview
18.25.2. Key Executives
18.25.3. Product & Services
18.26. Thermo Fisher Scientific, Inc.
18.26.1. Business Overview
18.26.2. Key Executives
18.26.3. Product & Services

19. Appendix
19.1. Discussion Guide
19.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2021 VS 2027
FIGURE 3. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 4. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 5. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2021 VS 2027 (USD MILLION)
FIGURE 6. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2027
FIGURE 7. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET DYNAMICS
FIGURE 8. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2021 VS 2027 (%)
FIGURE 9. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2021 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY TECHNOLOGY, 2027
FIGURE 11. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, 2018-2027 (USD MILLION)
FIGURE 12. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, 2018-2027 (USD MILLION)
FIGURE 13. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2027 (USD MILLION)
FIGURE 14. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, 2018-2027 (USD MILLION)
FIGURE 15. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, 2018-2027 (USD MILLION)
FIGURE 16. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2021 VS 2027 (%)
FIGURE 17. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2021 VS 2027 (USD MILLION)
FIGURE 18. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY CANCER TYPE, 2027
FIGURE 19. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2018-2027 (USD MILLION)
FIGURE 20. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, 2018-2027 (USD MILLION)
FIGURE 21. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2018-2027 (USD MILLION)
FIGURE 22. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2018-2027 (USD MILLION)
FIGURE 23. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2021 VS 2027 (%)
FIGURE 24. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2021 VS 2027 (USD MILLION)
FIGURE 25. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY FUNCTION, 2027
FIGURE 26. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, 2018-2027 (USD MILLION)
FIGURE 27. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2027 (USD MILLION)
FIGURE 28. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, 2018-2027 (USD MILLION)
FIGURE 29. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, 2018-2027 (USD MILLION)
FIGURE 30. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2027 (USD MILLION)
FIGURE 31. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 32. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD MILLION)
FIGURE 33. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2027
FIGURE 34. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, 2018-2027 (USD MILLION)
FIGURE 35. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, 2018-2027 (USD MILLION)
FIGURE 36. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, 2018-2027 (USD MILLION)
FIGURE 37. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, 2018-2027 (USD MILLION)
FIGURE 38. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2027 (USD MILLION)
FIGURE 39. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 40. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 41. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 42. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 43. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 44. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 45. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 46. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 47. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 48. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2021

List of Tables

TABLE 1. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2021
TABLE 3. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR, BY STATE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, 2018-2027 (USD MILLION)
TABLE 13. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY STATE, 2018-2027 (USD MILLION)
TABLE 14. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, 2018-2027 (USD MILLION)
TABLE 15. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY STATE, 2018-2027 (USD MILLION)
TABLE 16. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2027 (USD MILLION)
TABLE 17. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2018-2027 (USD MILLION)
TABLE 18. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 19. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, 2018-2027 (USD MILLION)
TABLE 20. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 21. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 23. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2018-2027 (USD MILLION)
TABLE 24. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY STATE, 2018-2027 (USD MILLION)
TABLE 25. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2027 (USD MILLION)
TABLE 26. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, 2018-2027 (USD MILLION)
TABLE 27. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY STATE, 2018-2027 (USD MILLION)
TABLE 28. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2027 (USD MILLION)
TABLE 29. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 30. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, 2018-2027 (USD MILLION)
TABLE 31. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 32. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, 2018-2027 (USD MILLION)
TABLE 33. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 34. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2027 (USD MILLION)
TABLE 35. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY STATE, 2018-2027 (USD MILLION)
TABLE 36. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 37. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, 2018-2027 (USD MILLION)
TABLE 38. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY STATE, 2018-2027 (USD MILLION)
TABLE 39. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, 2018-2027 (USD MILLION)
TABLE 40. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 41. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, 2018-2027 (USD MILLION)
TABLE 42. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 43. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, 2018-2027 (USD MILLION)
TABLE 44. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 45. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, 2018-2027 (USD MILLION)
TABLE 46. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY STATE, 2018-2027 (USD MILLION)
TABLE 47. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 48. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 49. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2027 (USD MILLION)
TABLE 50. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2027 (USD MILLION)
TABLE 51. CALIFORNIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 52. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 53. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 54. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2027 (USD MILLION)
TABLE 55. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2027 (USD MILLION)
TABLE 56. FLORIDA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 57. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 58. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 59. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2027 (USD MILLION)
TABLE 60. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2027 (USD MILLION)
TABLE 61. ILLINOIS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 62. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 63. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 64. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2027 (USD MILLION)
TABLE 65. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2027 (USD MILLION)
TABLE 66. NEW YORK NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 67. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 68. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 69. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2027 (USD MILLION)
TABLE 70. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2027 (USD MILLION)
TABLE 71. OHIO NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 72. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 73. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 74. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2027 (USD MILLION)
TABLE 75. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2027 (USD MILLION)
TABLE 76. PENNSYLVANIA NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 77. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 78. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2027 (USD MILLION)
TABLE 79. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2027 (USD MILLION)
TABLE 80. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2027 (USD MILLION)
TABLE 81. TEXAS NEXT GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 82. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 83. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 84. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 85. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET RANKING, BY KEY PLAYER, 2021
TABLE 86. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 87. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET MERGER & ACQUISITION
TABLE 88. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 89. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 90. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET INVESTMENT & FUNDING
TABLE 91. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 92. UNITED STATES NEXT GENERATION CANCER DIAGNOSTICS MARKET: LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Adaptive Biotechnologies Inc.
Agendia Nv
Agilent Technologies, Inc
Akadeum Life Sciences
Almac Group
Ambry Genetics
Becton, Dickinson And Co.
Biological Dynamics Inc.
Castle Biosciences Inc.
Danaher Corporation
Exosome Diagnostics, Inc.
F. Hoffmann-La Roche Ltd
GE Healthcare
Genomic Health, Inc.
Hologic, Inc
Illumina, Inc.
Janssen Global Services, LLC
Koninklijke Philips N.V.
Myriad Genetics, Inc.
Novartis AG
Opko Health, Inc.
Perkin Elmer, Inc.
Qiagen N.V.
Sysmex Corporation
Thermo Fisher Scientific, Inc.